Psychemedics Revenue 2012-2024 | PMD
Psychemedics revenue from 2012 to 2024. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
|
Psychemedics Annual Revenue (Millions of US $) |
|
|---|---|
| 2024 | $20 |
| 2023 | $22 |
| 2022 | $25 |
| 2021 | $25 |
| 2020 | $21 |
| 2019 | $38 |
| 2018 | $43 |
| 2017 | $40 |
| 2016 | $39 |
| 2015 | $27 |
| 2014 | $29 |
| 2013 | $27 |
| 2012 | $25 |
| 2011 | $24 |
|
Psychemedics Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2024-12-31 | $4 |
| 2024-09-30 | $5 |
| 2024-06-30 | $5 |
| 2024-03-31 | $5 |
| 2023-12-31 | $5 |
| 2023-09-30 | $6 |
| 2023-06-30 | $6 |
| 2023-03-31 | $6 |
| 2022-12-31 | $6 |
| 2022-09-30 | $7 |
| 2022-06-30 | $7 |
| 2022-03-31 | $7 |
| 2021-12-31 | $6 |
| 2021-09-30 | $7 |
| 2021-06-30 | $6 |
| 2021-03-31 | $6 |
| 2020-12-31 | $5 |
| 2020-09-30 | $5 |
| 2020-06-30 | $3 |
| 2020-03-31 | $8 |
| 2019-12-31 | $9 |
| 2019-09-30 | $10 |
| 2019-06-30 | $9 |
| 2019-03-31 | $10 |
| 2018-12-31 | $10 |
| 2018-09-30 | $11 |
| 2018-06-30 | $11 |
| 2018-03-31 | $11 |
| 2017-12-31 | $10 |
| 2017-09-30 | $10 |
| 2017-06-30 | $10 |
| 2017-03-31 | $10 |
| 2016-12-31 | $11 |
| 2016-09-30 | $12 |
| 2016-06-30 | $10 |
| 2016-03-31 | $7 |
| 2015-12-31 | $6 |
| 2015-09-30 | $7 |
| 2015-06-30 | $7 |
| 2015-03-31 | $7 |
| 2014-12-31 | $7 |
| 2014-09-30 | $8 |
| 2014-06-30 | $8 |
| 2014-03-31 | $7 |
| 2013-12-31 | $6 |
| 2013-09-30 | $7 |
| 2013-06-30 | $7 |
| 2013-03-31 | $6 |
| 2012-12-31 | $6 |
| 2012-09-30 | $6 |
| 2012-06-30 | $7 |
| 2012-03-31 | $6 |
| 2011-12-31 | $6 |
| 2011-09-30 | $6 |
| 2011-06-30 | $6 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Outpatient & Home Care | $0.000B | $0.020B |
| Psychemedics Corporation provides testing services for the detection of abused substances through the analysis of hair samples. Their testing methods utilize a patented technology for performing immunoassays on enzymatically dissolved hair samples with confirmation testing by mass spectrometry. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fresenius SE (FSNUY) | Germany | $29.514B | 13.37 |
| Quest Diagnostics (DGX) | United States | $21.197B | 19.44 |
| Elanco Animal Health (ELAN) | United States | $11.500B | 24.35 |
| Encompass Health (EHC) | United States | $10.662B | 19.64 |
| DaVita (DVA) | United States | $10.023B | 13.82 |
| Chemed (CHE) | United States | $5.639B | 19.57 |
| Option Care Health (OPCH) | United States | $4.553B | 18.71 |
| RadNet (RDNT) | United States | $4.302B | 142.13 |
| LifeStance Health (LFST) | United States | $2.495B | 320.00 |
| Addus HomeCare (ADUS) | United States | $1.719B | 16.61 |
| Astrana Health (ASTH) | United States | $1.536B | 31.40 |
| Aveanna Healthcare Holdings (AVAH) | United States | $1.353B | 12.20 |
| U.S Physical Therapy (USPH) | United States | $1.157B | 29.19 |
| Pennant (PNTG) | United States | $1.072B | 31.31 |
| Daxor (DXR) | United States | $0.048B | 0.00 |
| MEDIROM Healthcare Technologies (MRM) | Japan | $0.032B | 0.00 |